The study was aimed to the evaluation of efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women. A prospective, multicenter, randomized study that included 112 pregnant women with asymptomatic bacteriuria was performed. 58 women were randomized in group 1 (cefixime [suprax solutab] 400 mg 1 time a day, 7 days), 54 women were included in group 2 (amoxicillin/clavulanate [amoksiklav] 625 mg 3 times a day, 7 days). The average age of the patients in group 1 was 25.2 +/- 6.6; in group 2--26.6 +/- 5.8 years. Physical examination, evaluation of complaints, collection of data on adverse reactions, and bacteriological analysis of urine were performed after enrollment in the study at visit 2 (day 10 +/- 1) and 3 (day 35 +/- 2). Comparable effectiveness of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women was found. Eradication of the pathogen and sustained bacteriological response were observed in 94.8 and 92.7% of women treated with cefixime, and in 98.2 and 92.5% of women treated with amoxicillin/clavulanate, respectively (P > 0.05). At the same time, the use of amoxicillin/clavulanate compared with cefixime significantly higher was followed by the development of adverse reactions (13% and 1.7; respectively; P = 0.02). Seven-day courses of cefixime at a dose 400 mg 1 time a day and amoxicillin/clavulanate at a dose of 625 mg 3 times a day are high-effective treatment regimens for asymptomatic bacteriuria in pregnant women in Russia. The use of amoxicillin/clavulanate is significantly more often accompanied by the development of adverse reactions compared with cefixime.

To determine the prevalence of the spectrum of pathogens, outcomes of asymptomatic bacteriuria (ASB) 809 pregnant women conducted culturing urine screening using a submersible Uricult trio of slides in each trimester. BB with the traditional diagnostic titer ( 105 CFU / ml) occurred in 10% of surveyed pregnant women, a low form of BB (102–104 CFU / ml) was diagnosed in 11,6%. In the absence of timely treatment in clinically manifest ASB expressed in 36,8% of UTI, low ASB in 30,9%. The percentage of self-healing in the ASB was 10,5 and 13,8% lower ASB. Escherichia coli was the leading pathogen, which sow from the urine of pregnant women with both classical (61,8%) and low ASB (34,0%). 7-day course of treatment amoxicillin/klavulonatom and cefixime have the same high cure rate ASB: eradication of microorganisms after rehabilitation 98.1% and 96.6% respectively. When rehabilitation ASB amoxicillin/klavulonatom 10 times more recorded adverse drug reactions (17,0%, p

The asymptomatic bacteriuria with classic diagnostic titer (> 105 КОЕ/ml) is registed in 10% pregnant women, the low form of asymptomatic bacteriuria (102-104 КОЕ/ml) is diagnosted in 11,6% patients. The factors of risk of asymptomatic bacteriuria were the urolithic disease, a renal developmental anomaly, the indications on early carried infections of urinary tracts. The asymptomatic uroinfection is revealed in pregnant women of reproductive age with low instruction level, the presence in case history of spontaneous abortion and the harmful habit smoking. It is established that the seven-day therapy by means of the amoxyclave and the supraxon have identically high value of effectiveness treatment of asymptomatic bacteriuria: 98,1% and 96,6%. The undesirable medicinal reactions at the use of amoxyclave were registed usually (17,0%, p

Asymptomatic bacteriuria (ASB) is found in 2,5-15% of pregnant women and if untreated, often complicated by the development of obstetric, urologic and perinatal pathology. Effective diagnosis and treatment of the ASB leads to a significant reduction in the frequency of these complications. "Gold standard" diagnostic ASB is two-fold urine culture with the definition of susceptibility of microorganisms to antibiotics. For screening ASB can be used urine dipstick for bacteriuria, leukocyturia, combinations and dipslide culture. ASB for the treatment of pregnant women is most advisable to use fosfomycin, amoxicillin/clavulanate, cefixime, or nitrofurantoin.